141 related articles for article (PubMed ID: 9744738)
1. Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas (Vincristine, actinomycin D, Cyclophosphamide VAC versus ifosfamide).
Simşek T; Uner M; Trak B; Erman O; Zorlu GC
Eur J Gynaecol Oncol; 1998; 19(4):405-7. PubMed ID: 9744738
[TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial.
Le Deley MC; Paulussen M; Lewis I; Brennan B; Ranft A; Whelan J; Le Teuff G; Michon J; Ladenstein R; Marec-Bérard P; van den Berg H; Hjorth L; Wheatley K; Judson I; Juergens H; Craft A; Oberlin O; Dirksen U
J Clin Oncol; 2014 Aug; 32(23):2440-8. PubMed ID: 24982464
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant vincristine, dactinomycin, and cyclophosphamide therapy in stage I uterine sarcomas. A pilot study.
van Nagell JR; Hanson MB; Donaldson ES; Gallion HH
Cancer; 1986 Apr; 57(8):1451-4. PubMed ID: 3948125
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy using vincristine, adriamycin, cyclophosphamide (VAC) alternating with ifosfamide and etoposide (IE) for advanced soft tissue sarcomas: a phase II study.
Palumbo R; Palmeri S; Gatti C; Villani G; Cesca A; Toma S
Oncol Rep; 1998; 5(1):69-72. PubMed ID: 9458296
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
Ruymann FB; Vietti T; Gehan E; Wiener E; Wharam M; Newton WA; Maurer H
J Pediatr Hematol Oncol; 1995 Nov; 17(4):331-7. PubMed ID: 7583389
[TBL] [Abstract][Full Text] [Related]
6. Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma.
Theis JG; Chan HS; Greenberg ML; Malkin D; Karaskov V; Moncica I; Koren G; Doyle J
Med Pediatr Oncol; 2000 Apr; 34(4):242-9. PubMed ID: 10742059
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy following surgery in the management of uterine sarcomas.
Szánthó A; Bálega J; Szabó I; Demeter A; Sipos N; Csapó Z; Papp Z
Eur J Gynaecol Oncol; 2003; 24(5):421-4. PubMed ID: 14584661
[TBL] [Abstract][Full Text] [Related]
8. Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France.
Corvest V; Marec-Bérard P; Lervat C; Pacquement H; Toulmonde M; Gentet JC; Laurence V; Cleirec M; Mansuy L; Bompas E; Castex MP; Taque S; Filhon B; Tabone MD; Verité C; Entz-Werle N; Saumet L; Guimard G; Pondrom M; Chevreau C; Flandrin J; Duranteau L; Rousset-Jablonski C; Brugières L; Jimenez M; Le Deley MC; Gaspar N; Fresneau B
Int J Cancer; 2023 Apr; 152(8):1659-1667. PubMed ID: 36250317
[TBL] [Abstract][Full Text] [Related]
9. On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus.
Dusenbery KE; Potish RA; Argenta PA; Judson PL
Am J Clin Oncol; 2005 Jun; 28(3):295-300. PubMed ID: 15923804
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long-term follow-up.
Odunsi K; Moneke V; Tammela J; Ghamande S; Seago P; Driscoll D; Marchetti D; Baker T; Lele S
Int J Gynecol Cancer; 2004; 14(4):659-64. PubMed ID: 15304162
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M
Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807
[TBL] [Abstract][Full Text] [Related]
12. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
[TBL] [Abstract][Full Text] [Related]
13. Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (adriamycin), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. A prospective trial.
Hempling RE; Piver MS; Baker TR
Am J Clin Oncol; 1995 Aug; 18(4):282-6. PubMed ID: 7625366
[TBL] [Abstract][Full Text] [Related]
14. Effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma: a conventional and network Meta-analysis.
Hua Q; Xu G; Zhao L; Zhang T
J Chemother; 2021 Sep; 33(5):319-327. PubMed ID: 33501892
[TBL] [Abstract][Full Text] [Related]
15. Treatment of advanced uterine sarcoma with vincristine, actinomycin D, and cyclophosphamide.
Hannigan EV; Freedman RS; Elder KW; Rutledge FN
Gynecol Oncol; 1983 Apr; 15(2):224-9. PubMed ID: 6687580
[TBL] [Abstract][Full Text] [Related]
16. Role of chemotherapy and biomolecular therapy in the treatment of uterine sarcomas.
Hensley ML
Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):773-82. PubMed ID: 21752717
[TBL] [Abstract][Full Text] [Related]
17. Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas.
Piver MS; Lele SB; Marchetti DL; Emrich LJ
J Surg Oncol; 1988 Aug; 38(4):233-9. PubMed ID: 3045423
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy in early uterine sarcoma.
Hannigan EV; Freedman RS; Rutledge FN
Gynecol Oncol; 1983 Feb; 15(1):56-64. PubMed ID: 6401640
[TBL] [Abstract][Full Text] [Related]
19. A case report of rhabdomyosarcoma of the uterus associated with uterine inversion.
Case AS; Kirby TO; Conner MG; Huh WK
Gynecol Oncol; 2005 Mar; 96(3):850-3. PubMed ID: 15721436
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
